Blood pressure for optimal health-related quality of life in hypertensive patients

Journal of Hypertension

Volumn 31, Issue 4, 2013, Pages 830-839

  Zygmuntowicz, Monika ^a   Owczarek, Aleksander ^b   Elibol, Adam ^a   Olszanecka Glinianowicz, Magdalena ^a   Chudek, Jerzy ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b Statistical Division   (Poland)

Author keywords

hypertension; optimal blood pressure; quality of life; SF 12

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; COMORBIDITY; FEMALE; HEALTH SURVEY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; SHORT FORM 12;

EID: 84875226157     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32835ebdd7     Document Type: Article

References (25)

1. Mancia G, Laurent S, Agabiti-Rosei E,Ambrosioni E, Burnier M, Caulfield MJ, et al. European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121-2158.
2. Forette F, Seux ML, Staessen JA. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352:1347-1351.
3. Trevisol DJ, Moreira LB, Fuchs FD. Health-related quality of life is worse in individuals with hypertension under drug treatment: results of population-based study. J Hum Hypertens 2011; 19:253-257.
4. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281:537-544.
5. Wiklund I, Halling K, Ryde'n-Bergsten T. Does lowering the blood pressure improve the mood? Quality-of-life results from the Hypertension Optimal Treatment (HOT) study. Blood Press 1997; 6:357-364.
6. Klocek M, Kawecka-Jaszcz K. Quality of life in patients with essential hypertension. Part II: Influence of clinical factors. Przegl Lek 2003; 60:101-106.
7. Cruickshank JM. Coronary flow reserve and the J-curve relation between DDP and myocardial infarction. BMJ 1988; 297:1227-1230.
8. Fletcher AE, Bulpitt CJ, Tuomilehto J, Browne J, Bossini A, Kawecka- Jaszcz K, et al. Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial. J Hypertens 1998; 16:1117-1124.
9. Zygmuntowicz M, Owczarek A, Elibol A, Chudek J. Comorbidities and quality of life in hypertensive patients. Pol Arch Med Wewn 2012; 122:333-340.
10. Ware JE, Kosinki M, Turner-Bowker DM, Gandek B. How to score version 2 of the SF-12v2R Health Survey (With a Supplement Documenting SF-12R Health Survey). Lincoln, RI: Quality Metric Incorporated; 2002.
11. Cleveland WS, Loader CL. Smoothing by local regression: principles and methods. In: Haerdle W, Schimek MG, editors. Statistical theory and computational aspects of smoothing. Heidelberg: Physica Verlag; 1996. pp.10-49.
12. Gutierrez RG, Linhart JM, Pitblado JS. Local polynomial regression and Stata plugins. Stata J 2003; 3:412-419.
13. O'Brien RM. A caution regarding rules of thumb for variance inflation factors. Quality Quantity 2007; 41:673-690.
14. Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drugs trials. J Hypertens 2002; 20:1461-1464.
15. Seux ML, Thijs L, Forette F. Correlates of cognitive status of old patients with isolated systolic hypertension: the Syst-Eur Vascular Dementia Project. J Hypertens 1998; 16:963-969.
16. Hansson L, Zanchetti A, Carruthers SG, Dahlo?f B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351:1755-1762.
17. Kusek JW, Lee JY, Smith DE, Milligan S, Faulkner M, Cornell CE, et al. Effect of blood pressure control and antihypertensive drug regimen on quality of life: the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin Trials 1996; 17:40S-46S.
18. Roca-Cusachs A, Dalfó A, Badia X. Relation between clinical and therapeutic variables and quality of life in hypertension. J Hypertens 2001; 19:1913-1919.
19. Korhonen PE, Kivela? SL, Kautiainen H. Health-related quality of life and awareness of hypertension. J Hypertens 2011; 29:2070-2074.
20. Nunes MI. The relationship between quality of life and adherence to treatment. Curr Hypertens Rep 2001; 3:462-465.
21. Wassertheil-Smoller S, Oberman A, Blaufox MD. The Trial of Antihypertensive Interventions and Management (TAIM) Study. Final results with regard to blood pressure, cardiovascular risk, and quality of life. Am J Hypertens 1992; 5:37-44.
22. Williams SA, Michelson EL, Cain VA, Yang M, Nesbitt SD, Egan BM, Julius S. An evaluation of the effects of an angiotensin receptor blocker on health-related quality of life in patients with high-normal blood pressure (prehypertension) in the trial of preventing hypertension (TROPHY). J Clin Hypertens (Greenwich) 2008; 10:436-442.
23. Aydemir O, Ozdemir C, Koroglu E. The impact of co-morbid conditions on the SF-36: a primary-care-based study among hypertensives. Arch Med Res 2005; 36:136-141.
24. Wang R, Zhao Y, He X, Ma X, Yan X, Sun Y, et al. Impact of hypertension on health-related quality of life in a population-based study in Shanghai, China. Public Health 2009; 123:534-539.
25. Holecki M, Duława J, Chudek J. Resistant hypertension in visceral obesity. Eur J Intern Med 2012; 23:643-648.